Sarepta Therapeutics
SRPT
$119.41
Share price
4.07%
Change (1 day)
24.24%
Change (1 year)
Categories
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.
Sarepta Therapeutics (SRPT) - Total liabilities
Total liabilities on the balance sheet as of June 2023 : $2.38 B
According to Sarepta Therapeutics 's latest financial reports the company's total liabilities are $2.38 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Sarepta Therapeutics - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $2.74 B | 23.58% |
| 2021-12-31 | $2.21 B | -0.13% |
| 2020-12-31 | $2.22 B | 121.27% |
| 2019-12-31 | $1.00 B | 64.75% |
| 2018-12-31 | $0.60 B | 17.55% |
| 2017-12-31 | $0.51 B | 493.44% |
| 2016-12-31 | $87.41 M | 4.77% |
| 2015-12-31 | $83.43 M | 76.1% |
| 2014-12-31 | $47.38 M | 6.77% |
| 2013-12-31 | $44.37 M | -45.43% |
| 2012-12-31 | $81.31 M | 248.22% |
| 2011-12-31 | $23.35 M | -52.14% |
| 2010-12-31 | $48.79 M | 34.06% |
| 2009-12-31 | $36.39 M | 271.25% |
| 2008-12-31 | $9.8 M | -20.01% |
| 2007-12-31 | $12.25 M | 288.98% |
| 2006-12-31 | $3.15 M | 14.66% |
| 2005-12-31 | $2.74 M | 22.15% |
| 2004-12-31 | $2.24 M | -40.03% |
| 2003-12-31 | $3.75 M | -26.77% |
| 2002-12-31 | $5.12 M | 56.11% |
| 2001-12-31 | $3.28 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | $41.24 B | 1,629.64% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | $1.91 B | -19.59% | 🇺🇸 USA |
 Novavax NVAX | $2.43 B | 2.31% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | $3.81 B | 59.81% | 🇺🇸 USA |
 Insmed INSM | $1.59 B | -33.11% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | $0.91 B | -61.48% | 🇺🇸 USA |
 Avidity Biosciences RNA | $51.6 M | -97.84% | 🇺🇸 USA |